Skip to main content
. 2018 Jun 7;8(13):3584–3596. doi: 10.7150/thno.25409

Figure 4.

Figure 4

Combined chemo-PDT of ODC-HPOCs by dampening chemoresistance and enhancing PDT at a single dose. (A) DOX accumulation in major organs and tumor. (B) Hypoxia mapping and DOX distribution in tumor at 24 h after intravenous injection of ODC-HPOCs. Hypoxic regions are circled by white dots, and white dashed lines indicate the distance from the interior tumor region. Scale bar, 50 μm. (C) Quantitative measurement of total fluorescence intensity of hypoxia and DOX in whole tumor tissue fluorescence images (n=7). (D-F) Two days after treatment with DOX+Ce6 and ODC-HPOCs, tumors were harvested. The mRNA levels of HIF-1α (D) and MDR1gene (E) were determined by QRT-PCR and normalized to the expression of GAPDH. The protein levels of P-gp were determined by western blotting (F). (G) Singlet oxygen measurement in vivo after administration of C-HSA and OC-HPOCs with laser irradiation at 6 h. (H) DNA damage (γH2AX as marker) in tumor tissue at 24 h after the enhanced chemotherapy (ODC-HPOCs without laser) and the combined chemo-PDT (ODC-HPOCs+laser). (I) Tumor growth curves of different groups after treatments. Statistical P-values: *P < 0.05, **P < 0.01. (J) Biosafety evaluation by H&E staining of the major organs at the end of the experiment. Scal bar, 200 μm.